News | December 23, 2025
Cupid reduces promoter pledged stake to 20%
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
